HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity.

Abstract
The pharmacokinetics and serum killing curves of amikacin, which was administered by a 30-minute intravenous infusion of single doses of 7.5 mg/kg and then 15 mg/kg, were investigated in six healthy volunteers who received the two doses in a crossover study with a washout period of 20 days. The serum killing curves were determined for four bacterial species: Escherichia coli, Serratia marcescens, Enterobacter cloacae, and Pseudomonas aeruginosa. All strains were serum resistant, and the bactericidal activity was analyzed by separating the early phase (first 5 h) and the late phase (24 h) of the killing curve. For the early phase, the bactericidal activity was evaluated by correlating an index of surviving bacteria with amikacin concentrations. This methodology allowed determination of two parameters: the maximal effective concentration and the lowest effective concentration. For the late phase, the threshold values separating bacteriostatic and bactericidal activities were lower than 10 mg/liter for each strain. The concentration dependence of amikacin bactericidal activity was confirmed for Escherichia coli and Enterobacter cloacae and, to a lesser extent, for Serratia marcescens and Pseudomonas aeruginosa. Correlation of these data with amikacin pharmacokinetic data in volunteers indicated that a daily dose of 15 mg/kg may be effective in the treatment of Escherichia coli and Enterobacter cloacae infections. For Pseudomonas aeruginosa and Serratia marcescens, the partially time-dependent activity probably necessitates two daily administrations and combination with another antibiotic.
AuthorsR Garraffo, H B Drugeon, P Dellamonica, E Bernard, P Lapalus
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 34 Issue 4 Pg. 614-21 (Apr 1990) ISSN: 0066-4804 [Print] United States
PMID2111658 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Amikacin
Topics
  • Adult
  • Amikacin (administration & dosage, blood, pharmacokinetics, pharmacology)
  • Colony Count, Microbial
  • Dose-Response Relationship, Drug
  • Enterobacter (drug effects)
  • Escherichia coli (drug effects)
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Pseudomonas aeruginosa (drug effects)
  • Serratia marcescens (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: